Zoryve (roflumilast) topical foam, 0.3% Phosphodiesterase type 4 inhibitor Treatment of plaque psoriasis of the scalp and body in adult and pediatric patients aged 12 years and older. Zoryve Foam 0.3% ...

Johnson & Johnson currently boasts one of the largest lineups of multiple myeloma products. Since its first FDA approval of a drug for this type of blood cancer a decade ago, the pharmaceutical ...

Analysts' ratings for Johnson & Johnson JNJ over the last quarter vary from bullish to bearish, as provided by 12 analysts. The following table encapsulates their recent ratings, offering a ...

“That was a genuine expression,” Vincent said in an interview this week. “We were so happy.” The business they’d just pitched was JNJ Gifts and More, which produces custom gift boxes for corporate ...

Credit: Johnson & Johnson. Nipocalimab-aahu is a human immunoglobulin G1 monoclonal antibody that binds with high affinity to the neonatal Fc receptor, resulting in the reduction of circulating ...

Johnson & Johnson JNJ announced positive top-line data from a late-stage study evaluating the combination of niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, plus ...

Concluding a recent interview with Jonathan Strober, MD, an investigator on the phase 2/3 Vibrance-MG study (NCT05265273) exploring pediatric use of nipocalimab for generalized myasthenia gravis ...

Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves lean mass and enhances fat loss, offering a potential advancement in ...

View our complete analysis and fair value estimate and you decide. NYSE:JNJ Revenue & Expenses Breakdown as at Jun 2025 The end of cancer? These 23 emerging AI stocks are developing tech that will ...